Knee OA drug combo trial ends early — only 23 enrolled

NCT ID NCT04814368

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two injected drugs, canakinumab and LNA043, for people with painful knee osteoarthritis. It aimed to see if they could reduce pain and improve cartilage. The trial was stopped early and included only 23 participants, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arthralgia osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS

Contacts and locations

Locations

Clinical Res Of W Florida

Clearwater, Florida, 33765, United States
Horizon Clinical Research

La Mesa, California, 91942, United States
LV Research

Las Vegas, Nevada, 89119, United States
Lucas Research

Morehead City, North Carolina, 28557, United States
Novartis Investigative Site

Prague, Czech Republic, 19000, Czechia
Novartis Investigative Site

Tartu, 50406, Estonia
Novartis Investigative Site

Kecskemét, Bács-Kiskun county, 6044, Hungary
Novartis Investigative Site

Budapest, 1036, Hungary
Novartis Investigative Site

Riga, 1005, Latvia
Novartis Investigative Site

Warsaw, 02-677, Poland
Precision Clinical Research LLC

Sunrise, Florida, 33351, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.